Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02326285
Recruitment Status : Terminated (Due to low patient enrollment was stopped. Only one patient could be enrolled. 37 patients were pre-screened, but not into the inclusion criteria (wt-EGFR))
First Posted : December 29, 2014
Last Update Posted : January 23, 2018
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
AIO-Studien-gGmbH

Brief Summary:

This study is designed as a single arm, un-controlled, open-label, multi-center hypothesis generating two-stage phase II trial. It is based on the assumption that the proposed treatment scheme doubles the rate of pathologic complete remission in Mutated epidermal growth factor receptor (EGFRmt) + NSCLC patients compared to historical control data from standard treatments.

Patients with NSCLC and activating EGFR mutation in stages II, IIIA and IIIB eligible for induction therapy with docetaxel and cisplatin and gefitinib

Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.


Condition or disease Intervention/treatment Phase
Non-squamous Non-small Cell Lung Cancer Stage II Non-squamous Non-small Cell Lung Cancer Stage IIIA Non-squamous Non-small Cell Lung Cancer Stage IIIB Activating EGFR Mutation NSCLC Drug: Gefitinib Drug: docetaxel Drug: cisplatin Procedure: Surgery Phase 2 Phase 3

Detailed Description:
Based on the notion that neoadjuvant combination of Chemotherapy (CTx) and intercalated TKI is clinically beneficial, which can be inferred from prior study data and single case reports, this study aims to generate additional information on feasibility, safety and efficacy of this treatment approach in a larger group of EGFR mutated NSCLC patients. This study is a hypothesis generating two-stage trial for future phase III studies of neoadjuvant CTx with intercalated TKI. Hence, the study design relies entirely on a single treatment arm. To demonstrate efficacy it is sufficient to compare to historical data of the conventional treatments of NSCLC.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Induction Therapy With Gefitinib Followed by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial.
Study Start Date : November 2015
Actual Primary Completion Date : March 28, 2017
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Gefitinib

Arm Intervention/treatment
Experimental: Treatment phase
Enrolled patients will be treated with 250mg/day Gefitinib for 11 days (day -12 until day -1) followed by 3 cycles (length 21 days) of chemotherapy with docetaxel (75mg/m2 d1) and cisplatin (50 mg/m2 d1+2) combined with intercalated gefitinib (250mg/day, d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
Drug: Gefitinib
Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
Other Name: IRESSA ®

Drug: docetaxel
chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).

Drug: cisplatin
chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).

Procedure: Surgery
Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).




Primary Outcome Measures :
  1. pathologic complete remission rate (pCR rate) [ Time Frame: 12 weeks (after 3 cycles and surgery) after enrollment ]
    The primary objective of the study is to assess the pathologic complete remission rate after induction therapy with gefitinib d -12 to d-1 followed by docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 q21 and intercalated gefitinib 250 mg d4 to d20 (cycle 1 and 2) and d4-17 (for cycle3), in order to demonstrate feasibility and efficacy of this treatment scheme. It is expected to achieve a pCR ≥30% regression grade IIB and III (Junker criteria) compared to historical controls in the mediastinal lymph nodes.


Secondary Outcome Measures :
  1. Adverse Events (AEs) / Serious adverse events (SAEs) [ Time Frame: 30 months ]
    AEs/SAEs from 21 patients during induction CTx with docetaxel and cisplatin in combination with intercalated gefitinib

  2. Surgical R0 resection rate [ Time Frame: 30 month ]
    R0 resection rate as assessed according to the German S3 guidelines

  3. Response: radiologic response based on CT [ Time Frame: 30 month ]
  4. progression free survival (PFS) [ Time Frame: 30 month ]
    Progression-free survival (PFS) will be defined as the time from enrollment to the time of disease progression or relapse or death, or to the date of last assessment without any such event (censored observation).

  5. Overall survival (OS) [ Time Frame: 30 month ]
    The duration of overall survival (OS) will be determined by measuring the time interval from enrollment to the date of death or last observation (censored).

  6. relapse pattern [ Time Frame: 30 month ]
    After the end of treatment will be performed every 3 month (+/- 14 days) for minimum 12 months in order to collect information on relapse and site of relapse

  7. quality of life [ Time Frame: 30 month ]
    Explorative analysis of health related quality of life, QoL at various time points throughout the study, to assess the QoL during and after induction therapy with gefitinib, after three cycles of chemotherapy with intercalated gefitinib including pre- and post surgery

  8. translational research [ Time Frame: 30 month ]
    To collect and store tumor tissue as well as plasma and serum samples for exploratory analyses of potential predictive markers, monitoring of biomarkers during and after treatment

  9. monitoring of epidermal growth factor receptor (EGFR) mutation status [ Time Frame: 30 month ]
    analysis of EGFR ctDNA in patient plasma; screening for EGFR mutation status (activating and resistance mutations especially T790M), monitoring of EGFR mutation status by means of Circulating tumor DNA (ctDNA) detection in patient plasma



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with histologically or cytologically confirmed non-squamous non-small-cell lung cancer (NSCLC) stage II, IIIA and IIIB detected preoperatively by adequate methods and activating EGFR mutation in exons 18-21 and deemed to be able to undergo curative surgery after induction therapy. Stage should be confirmed by PET-CT as well as adequate mediastinal staging. MRI of the brain to exclude CNS metastases is mandatory.
  2. At least one unidimensionally measurable lesion meeting RECIST criteria (version 1.1);
  3. Performance status of 0 to 1 on the ECOG scale;
  4. Estimated life expectancy of at least 12 weeks;
  5. Patients aged ≥ 18 years;
  6. Adequate organ function including the following:

    1. Adequate bone marrow reserve:

      • absolute neutrophils (segmented and bands) count (ANC) ≥1.5x109/L;
      • platelets ≥100x109/L;
      • haemoglobin ≥9 g/dL.
    2. Hepatic:

      • bilirubin ≤ 1xULN;
      • alkaline phosphatase (AP);
      • aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5xULN.
    3. Renal:

      • serum creatinine ≤ 1.3 mg/dL
      • glomerular filtration rate (GFR) ≥ 70 mL/min for cisplatinum based CTx;
      • If contraindications including GFR below 70mL/minagainst cisplatin exist, carboplatin may also be used;
      • glomerular filtration rate ≥ 30 mL/min (calculated) if carboplatin is to be used
  7. Adequate lung function tests as assessed by body plethysmography, diffusion test and if necessary spiro-ergometry.
  8. Cooperation and willingness to complete all aspects of the study;

    • Written informed consent to participate in the study.

Exclusion Criteria:

  1. EGFR wild type configuration;
  2. EGFR resistance mutations (i.e. T790M);
  3. Significant cardiovascular disease, such as uncontrolled hypertension, myocardial infarction within the last 6 months, unstable angina pectoris, CHF ≥ NYHA 2, serious arrhythmia, significant peripheral vascular disease;
  4. Pre-existing neuropathic ≥ grade 2;
  5. Patients with confirmed HIV infection. HIV testing is not mandatory.
  6. Prior history of malignancy except for basal cell carcinoma or carcinoma in situ of the cervix, and with the exception of other malignancies after curative treatment with an interval of at least 3 years.
  7. Lactating or pregnant woman, woman of child-bearing potential who do not agree to the usage of highly effective contraception methods (allowed methods of contraception, meaning methods with a rate of failure of less than 1% per year are implants, injectable contraceptives, combined oral contraceptives, intrauterine devices (only hormonal devices), sexual abstinence or vasectomy of the partner). Woman of childbearing potential must have a negative pregnancy test (serum β-HCG) at visit 1.
  8. Any other chemotherapy at start;
  9. Treatment with other experimental drugs during the course of the study or within the last 30 days or 7 half-lifes, whatever is of longer duration, prior study start;
  10. Any psychiatric illness that would affect the patient's ability to understand the demands of the clinical trial;
  11. Parallel participation in another clinical trial or participation in another clinical trial within the last 30 days or 7 half-lifes, whatever is of longer duration, prior study start;
  12. Patient has already been included in this trial;
  13. Patients who do not understand the nature, the scope and the consequences of the clinical trial;
  14. Affected persons who might be dependent on the sponsor or the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02326285


Locations
Layout table for location information
Germany
Pius-Hospital
Oldenburg, Germany, 26121
Sponsors and Collaborators
AIO-Studien-gGmbH
AstraZeneca
Investigators
Layout table for investigator information
Principal Investigator: Frank Griesinger, Prof. Dr. Universitätsklinik für Innere Medizin-Onkologie, Pius-Hospital, Oldenburg

Additional Information:
Layout table for additonal information
Responsible Party: AIO-Studien-gGmbH
ClinicalTrials.gov Identifier: NCT02326285     History of Changes
Other Study ID Numbers: AIO-TRK-0214
2014-005595-28 ( EudraCT Number )
IISR ESR-14-10598 ( Other Identifier: AstraZeneca )
First Posted: December 29, 2014    Key Record Dates
Last Update Posted: January 23, 2018
Last Verified: January 2018
Keywords provided by AIO-Studien-gGmbH:
induction therapy
NSCLC
Non-small Cell Lung Cancer
curative surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Cisplatin
Docetaxel
Gefitinib
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors